Int’l drugmakers accelerate research input in China
Thursday, 6 September 2007
BEIJING, Sept. 5 (CEIS): International drugmakers have accelerated their pace to establish research input in China for new patented medicines.
During an ongoing conference held by International Pharmaceutical Federation(FIP) in Beijing, pharmaceutist like AstraZeneca, GlaxoSmithKline, Lilly and Pfizer have all displayed their research bases or centers in China.
A report released by the National Development and Reform Commission in July revealed that a lot of international drugmakers have moved research and developing sectors to China.
International drugmakers have so far invested more than 500 million U.S. dollars to establish research centers in China.
Doctor Wang Xiaoliang, director of institute of Materia Medica, Chinese Academy of Medical Sciences, believed that some Chinese industrial zones like Zhangjiang Hi-tech Park in Shanghai have become places attracting foreign drugmakers.
During an ongoing conference held by International Pharmaceutical Federation(FIP) in Beijing, pharmaceutist like AstraZeneca, GlaxoSmithKline, Lilly and Pfizer have all displayed their research bases or centers in China.
A report released by the National Development and Reform Commission in July revealed that a lot of international drugmakers have moved research and developing sectors to China.
International drugmakers have so far invested more than 500 million U.S. dollars to establish research centers in China.
Doctor Wang Xiaoliang, director of institute of Materia Medica, Chinese Academy of Medical Sciences, believed that some Chinese industrial zones like Zhangjiang Hi-tech Park in Shanghai have become places attracting foreign drugmakers.